ArticleScience (New York, N.Y.)2021
Vaccine nationalism and the dynamics and control of SARS-CoV-2.
Article in Science (New York, N.Y.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Real-Word Effectiveness of Global COVID-19 Vaccines Against SARS-CoV-2 Variants: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2022Pooled it
- Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care.The Lancet. Respiratory medicine · 2023Trial
- Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.The New England journal of medicine · 2022Trial
- The Process Is Not the Point: Moral Uncertainty and Substantive Justice in Health Care Priority Setting.Bioethics · 2026Article
- Evaluation of consistency in adverse event reporting between trial registry and publications in COVID-19 pharmacological intervention trials.International journal of clinical pharmacy · 2026Article
- Economic factors promoting vaccine nationalism in the face of viral evolution.PLoS computational biology · 2026Article
- Global disparities in COVID-19 vaccine coverage associated with trajectories of SARS-CoV-2 adaptation.BMC infectious diseases · 2026Article
- Epidemiological impacts of nonpharmaceutical interventions are modulated by immunity exposure trade offs.Communications medicine · 2026Article
- Observational
- Global disparities in the introduction, scale-up, and effectiveness evaluation of COVID-19 vaccines.Nature communications · 2025Article
- Quantifying the impact of a broadly protective sarbecovirus vaccine in a future SARS-X pandemic.Nature communications · 2025Article
- Completeness and changes in data reporting pharmacological interventions to treat COVID-19.Scientific reports · 2025Article
- Social dilemma of nonpharmaceutical interventions: Determinants of dynamic compliance and behavioral shifts.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- A systemic evaluation of COVID-19 vaccination drives in LICs, LMICs, UMICs, and HICs: Preparedness for future pandemics.Journal of family medicine and primary care · 2024Article
- Vaccine equity implementation: exploring factors influencing COVID-19 vaccine delivery in the Philippines from an equity lens.BMC public health · 2024Article
- The evolution of post-infection mortality.Proceedings. Biological sciences · 2024Article
- Adaptive human behaviour modulates the impact of immune life history and vaccination on long-term epidemic dynamics.Proceedings. Biological sciences · 2024Article
- Impact of waning immunity against SARS-CoV-2 severity exacerbated by vaccine hesitancy.PLoS computational biology · 2024Article
- Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trial.The British journal of general practice : the journal of the Royal College of General Practitioners · 2024Article
- Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccines provide powerful tools to mitigate the enormous public health and economic costs that the ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues to exert globally, yet vaccine distribution remains unequal among countries. To examine the potential epidemiological and evolutionary impacts of “vaccine nationalism,” we extend previous models to include simple scenarios of stockpiling between two regions. In general, when vaccines are widely available and the immunity they confer is robust, sharing doses minimizes total cases across regions. A number of subtleties arise when the populations and transmission rates in each region differ, depending on evolutionary assumptions and vaccine availability. When the waning of natural immunity contributes most to evolutionary potential, sustained transmission in low-access regions results in an increased potential for antigenic evolution, which may result in the emergence of novel variants that affect epidemiological characteristics globally. Overall, our results stress the importance of rapid, equitable vaccine distribution for global control of the pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.